Pulse Biosciences, INC Form 4 insider transactions

Director Mahkam Zanganeh was granted stock options for 44,504 shares of Pulse Biosciences common stock.

Director Richard van den Broek was granted 38,423 stock options in Pulse Biosciences, Inc. as part of a compensation update.

Director Robert W. Duggan was granted 42,495 stock options in Pulse Biosciences, Inc. as disclosed in a recent SEC Form 4 filing.

Director Manmeet Singh Soni was granted 30,000 stock options in Pulse Biosciences, Inc. as part of a compensation package.

Director Maria Sainz was granted 33,793 stock options in Pulse Biosciences, Inc. as part of a compensation update.

Director and 10% owner Robert W. Duggan acquired 660,233 shares of Pulse Biosciences common stock through an at-the-market offering.

Pulse Biosciences CEO Paul A. Laviolette acquired 15,000 shares of common stock through the company's at-the-market offering program.

Pulse Biosciences CEO Paul A. Laviolette acquired 15,000 shares of common stock through the company's at-the-market offering program.

Director and 10% owner Robert W. Duggan acquired 660,233 shares of Pulse Biosciences common stock through an at-the-market offering.

Pulse Biosciences, Inc. reports a grant of 100,000 Restricted Stock Units to Chief Technology Officer Darrin Uecker.

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, executed pre-planned option exercises and subsequent sales of common stock.

Maria Sainz, a Director at Pulse Biosciences, received grants for 53,104 common stock options with varying vesting schedules.

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, exercised stock options and subsequently sold 4,600 shares of common stock under a pre-arranged trading plan.

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, filed a Form 4 detailing future planned exercises of stock options and subsequent sales of common stock under a Rule 10b5-1 trading plan.

Pulse Biosciences' Chief Technology Officer, Darrin Uecker, reported exercising stock options and selling common stock totaling 45,000 shares under a pre-arranged 10b5-1 trading plan.

Pulse Biosciences' Chief Technology Officer, Darrin Uecker, executed a planned sale of 75,000 common shares in September 2025, following the exercise of stock options.

Pulse Biosciences Director and 10% owner Robert W. Duggan acquired 192,599 shares of common stock across three transactions in September 2024 and September 2025.

Pulse Biosciences Director Richard van den Broek was granted 30,000 stock options with a $16.16 exercise price, vesting monthly over one year.

Pulse Biosciences Director Mahkam Zanganeh was granted 54,134 stock options with an exercise price of $16.16, vesting over one year.

Robert W. Duggan, a Director and 10% owner of Pulse Biosciences, Inc., was granted 50,792 stock options with an exercise price of $16.16.

Pulse Biosciences Director Manmeet Singh Soni was granted 30,000 stock options with an exercise price of $16.16, vesting monthly over one year.

Pulse Biosciences, Inc. granted 55,000 stock options to Principal Accounting Officer Steven Weber with a $16.03 exercise price, vesting based on time and market capitalization milestones.

Pulse Biosciences' Chief Technology Officer and Director, Darrin Uecker, sold a total of 30,000 shares of common stock over two days in June 2025, pursuant to a Rule 10b5-1 trading plan.

Director Mahkam Zanganeh reports acquisition and disposal of Pulse Biosciences stock and warrants.

Pulse Biosciences CEO, Paul A. Laviolette, was granted stock options for 1.5 million shares, vesting over time and based on performance targets.

Former Pulse Biosciences CEO Burke Barrett sells 50,000 shares and agrees to disgorge short-swing profits from a prior rights offering purchase.

Robert W. Duggan, a director at Pulse Biosciences, exercised warrants to purchase shares of the company's common stock at $11 per share on December 18, 2024.

Robert W. Duggan, a director at Pulse Biosciences, purchased 55,256 shares of common stock at a price of $17.18 per share on December 13, 2024.

Robert W. Duggan, a director at Pulse Biosciences, purchased 45,404 shares of common stock at a weighted average price of $17.13 on December 12, 2024.